Section of Hematology and Coagulation, Department of Internal Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
Department of Public Health, McKillop Health Institute, Australian Catholic University, Melbourne, Australia.
Leuk Lymphoma. 2021 Jan;62(1):211-217. doi: 10.1080/10428194.2020.1817437. Epub 2020 Sep 10.
The risk for hip and vertebral fracture was determined in 10,752 patients diagnosed with myeloproliferative neoplasms (MPN) in Sweden 1995-2015. The mean follow-up time were 6.34 years. Five percent developed hip fracture and 1.3% a vertebral fracture. There was a significant increased risk for fracture among the MPN patients compared with the Swedish population. The ratio of observed (obs) and expected (exp) number of hip fracture in all MPN patients, polycythemia vera (PV), essential thrombocythemia and MPN undetermined (MPNu) was 1.20 (95% confidence interval (CI): 1.10-1.31), 1.37 (95% CI: 1.19-1.58), 1.02 (95% CI: 0.87-1.19), and 1.28 (95% CI: 1.07-1.52), respectively. Corresponding figures for vertebral fractures were 1.94 (95% CI: 1.64-2.29), 2.09 (95% CI: 1.56-2.75), 1.50 (95% CI: 1.06-2.07) and 2.47 (95% CI: 1.77-3.35), respectively. Patients with MPN had an increased risk of hip and vertebral fracture, especially patients with PV and MPNu in comparison with the entire Swedish population.
在 1995 年至 2015 年期间,对瑞典的 10752 名骨髓增生性肿瘤(MPN)患者进行了髋部和椎体骨折风险的确定。平均随访时间为 6.34 年。5%的患者发生髋部骨折,1.3%的患者发生椎体骨折。与瑞典人群相比,MPN 患者发生骨折的风险显著增加。所有 MPN 患者、真性红细胞增多症(PV)、原发性血小板增多症和 MPN 不确定(MPNu)患者的观察到(obs)和预期(exp)髋部骨折数之比为 1.20(95%置信区间(CI):1.10-1.31)、1.37(95% CI:1.19-1.58)、1.02(95% CI:0.87-1.19)和 1.28(95% CI:1.07-1.52)。相应的椎体骨折数据分别为 1.94(95% CI:1.64-2.29)、2.09(95% CI:1.56-2.75)、1.50(95% CI:1.06-2.07)和 2.47(95% CI:1.77-3.35)。与整个瑞典人群相比,MPN 患者髋部和椎体骨折的风险增加,尤其是 PV 和 MPNu 患者。